China-based biotechnology company MGI Tech Co., Ltd. (MGI) announced on Sunday that it has collaborated with the Universidad de San Martin de Porres (USMP), a private nonprofit university located in the city of Lima, Peru to implement next-generation genomic sequencing technologies in the university's Genetic and Molecular Biology Research Center.

This collaboration aims to identify genetic risk factors within the Peruvian population to inform future public health treatments. A university study revealed that 70% of the Peruvian population has indigenous genetic heritage, emphasizing the importance of tailored genetic research for precise healthcare solutions.

Dr Fujita and a team of seven researchers will spearhead five research projects. Rare diseases research will target conditions such as neurological and developmental disorders. Cancer research will focus on 200 cases of sporadic cancers over two years to study hereditary predispositions and genetic markers. Immunogenomics will explore genetic variants influencing infection susceptibility, while a four-year project will sequence 1,000 genomes from South American native populations to support a Peruvian BioBank. Metagenomics efforts will analyze 1,000 samples to investigate microorganisms and human microbiomes in the Andes and Amazon regions.